Company intelligence / Profile preview
Curative Biotechnology, Inc.
- Ownership
- Public · CUBT
- Employees
- ~4
- Development stage
- Preclinical
Overview
Curative Biotechnology has completed IND-enabling studies for its metformin eye drop formulation targeting AMD. The company is preparing for first-in-human clinical trials in collaboration with the National Eye Institute. Other programs are at preclinical or early clinical stages.[5][9]
- Therapeutic areas
- OphthalmologyOncologyInfectious Diseases
- Modalities
- Small molecules (e.g., metformin reformulation)Monoclonal antibodies (e.g., CD56 mAb ADC)Immunotherapies/adjuvants (e.g., IMT504)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Financials
- Market cap
- $6.8M
- Total revenue
- $0
- Enterprise value
- $8M
Beyond the preview
Go deeper on Curative Biotechnology, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curative Biotechnology, Inc..